Commitments and Contingencies - Additional Information (Details)	1 Months Ended		3 Months Ended		22 Months Ended
	Jun. 30, 2022 USD ($)	Jan. 31, 2021 USD ($)	Mar. 31, 2024 USD ($) Milestone	Mar. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)
Lilly Agreement
Loss Contingencies [Line Items]
Upfront payment		$ 5,000,000
Royalties incurred			$ 0
Lilly Agreement | Maximum
Loss Contingencies [Line Items]
Tiered percentage royalty on annual net sales		10.00%
Akoya Agreement
Loss Contingencies [Line Items]
Upfront payment	$ 600,000
Obligation to pay upon achievement of specified development milestones	$ 17,300,000
Milestone payments					$ 8,300,000
Number of milestones achieved | Milestone			0
Research and Development Expense | Akoya Agreement
Loss Contingencies [Line Items]
Milestones expenses				$ 1,500,000
Development and Commercial Milestone | Lilly Agreement
Loss Contingencies [Line Items]
Milestone payments		$ 168,000,000